Adlai Nortye (NASDAQ: ANL) is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. Assembled a world-class management team, built unique immuno-oncology platforms, and partnered with multiple top pharmaceutical companies to promote innovation.